Entelos
Appoints Jon S. Saxe Chairman of the Board
Menlo
Park, Calif., October 7, 2002 –
Entelos, Inc., the leader in predictive biosimulation for in
silico drug discovery and development, announced today the appointment
of Jon S. Saxe as Chairman of the Board.
From
January 1995 to May 1999, Mr. Saxe was President of Protein Design Labs,
Inc. a leader in the development of humanized antibodies, and continues to
serve as a Director. He is also an Executive-in-Residence at Institutional
Venture Partners, a venture capital firm. In addition, Mr. Saxe is a
Director of RiboGene Inc., Incyte Genomics, ID Biomedical Corporation and
POINT Biomedical Corporation and several other companies.
“We
are delighted to have someone of Jon’s experience and capability as our
Chairman. Jon brings a wealth
of leadership experience and industry knowledge to Entelos and will be
invaluable in supporting our continued growth and development” stated
James Karis, President and CEO of Entelos, Inc.
Mr.
Saxe served as President of Saxe Associates, a biotechnology and
pharmaceutical consulting firm, from May 1993 to December 1994. He served
as President, Chief Executive Officer and as a Director of Synergen, Inc.,
a biopharmaceutical company, from October 1989 to April 1993. From August
1984 through September 1989, Mr. Saxe was Vice President, Licensing and
Corporate Development at Hoffmann-LaRoche and Head of Patent Law at the
company from September 1978 through September 1989. Mr. Saxe received his
B.S. in Chemical Engineering from Carnegie-Mellon University, a J.D. from
George Washington University School of Law, and his LL.M. from New York
University School of Law.
Entelos,
Inc. (www.entelos.com), headquartered in Menlo Park, California, is the
leader in predictive biosimulation for in
silico drug discovery and development. The company’s patented
PhysioLab® technology provides a breakthrough platform for testing
experiments and hypotheses in silico,
predicting the results through simulation, and creating knowledge out of
fragmented discovery and clinical data. Entelos provides integrated
expertise in the metabolic, immunologic, and respiratory areas, and
currently offers PhysioLab systems for asthma, obesity, diabetes, and
rheumatoid arthritis. Access to Entelos technology and expertise is
available through R&D collaborations, research agreements, and
licensing. The company plans to expand its in
silico R&D capabilities based on its PhysioLab technology for a
wide variety of disease areas.
This press release contains forward-looking
statements that are subject to risks and uncertainties that could cause
actual results to differ materially from those set forth in the
forward-looking statements. Actual
results may differ materially from those projected. Entelos disclaims,
however, any intent or obligations to update these forward-looking
statements.
###
Entelos
is a registered trademark of Entelos, Inc.
All other trademarks are the property of their registered owners.
Contacts:
